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Abstract
Background: Penile cancer is a rare malignancy in Western countries, with an incidence rate of around 1 per
100,000. Due to its rarity, most treatment recommendations are based on small trials and case series reports.
Furthermore, data on the resource implications are scarce. The objective of this study was to estimate the annual
economic burden of treating penile cancer in England between 2006 and 2011 and the cost of treating a single
case based on a modified version of the European Association of Urology penile cancer treatment guidelines.
Methods: A retrospective (non-comparative) case series was performed using data extracted from Hospital Episode
Statistics. Patient admission data for invasive penile cancer or carcinoma in situ of the penis was extracted by ICD-10
code and matched to data from the 2010/11 National Tariff to calculate the mean number of patients and associated
annual cost. A mathematical model was simultaneously developed to estimate mean treatment costs per patient
based on interventions and their associated outcomes, advised under a modified version of the European Association
of Urologists Treatment Guidelines.
Results: Approximately 640 patients per year received some form of inpatient care between 2006 and 2011,
amounting to an average of 1,292 spells of care; with an average of 48 patients being treated in an outpatient
setting. Mean annual costs per invasive penile cancer inpatient and outpatient were £3,737 and £1,051 respectively,
with total mean annual costs amounting to £2,442,020 (excluding high cost drugs). The mean cost per case, including
follow-up, was estimated to be £7,421 to £8,063. Results were sensitive to the setting in which care was delivered.
Conclusions: The treatment of penile cancer consumes similar levels of resource to other urological cancers. This
should be factored in to decisions concerning new treatment modalities as well as choices around resource allocation
in specialist treatment centres and the value of preventative measures.
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Background
Invasive penile cancer is a rare neoplasm accounting for
less than 0.5 % of all cancers worldwide [1] and most
commonly affects men aged 50-70 years [2]. A recent
epidemiological study reported an age-standardized inci-
dence rate of 1.33 per 100,000 in 2009, a 21 % increase
from estimates 30 years prior [3]. The majority of pa-
tients will have five year disease specific survival of over
90 % despite local recurrence being relatively common
(~20 %) [4]. Associated risk factors include a lack of
neonatal circumcision, phimosis, cigarette smoking, first
sexual intercourse at an early age and human papilloma-
virus (HPV) infection [5, 6].
Despite a number of associated risk factors, the exact
aetiology of penile cancer remains ambiguous. An esti-
mated 60-100 % of penile intraepithelial neoplasia and
40-50 % of invasive penile tumours are however postu-
lated to be attributable to HPV infection [5]. A review of
31 studies investigating the prevalence of HPV in inva-
sive penile tumours found that 60.2 % of subjects had
positive traces of HPV 16, followed by HPV 18 and HPV
6/11 (13.3 % and 8.13 %, respectively) [7].
Treatment of penile cancer is influenced by several
factors, including tumour size and its location with re-
spect to the glans. Surgical intervention is deemed the
gold standard for high grade and high stage disease; ab-
lative surgery exhibits lower risk of recurrence than con-
servative surgery (5 % vs. 27 %). The pathological
assessment of surgical margins is imperative as positive
results inevitably lead to local recurrence [8].
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All treatments have a potentially detrimental impact
on quality of life including issues due to disfigurement,
sexual function, social interactions, self-image and self-
esteem. Rehabilitation and post-treatment care are vital
components in the treatment pathway for penile cancers
and are often overlooked in cost-of-illness studies [9].
In a recent study conducted in France, penile cancer
was associated with a total annual cost of €5.6 million
(excluding expensive drug costs) based on 678 hospita-
lised patients. The total cost comprised €2.6 million hos-
pitalisation costs, €2.3 million outpatient costs and €0.7
million daily allowance costs [6].
To our knowledge, no detailed estimates of the eco-
nomic burden associated with penile cancer in England
are currently available. Such data would be valuable for
evaluating both the value of new treatments for penile
cancer and also preventative strategies such as HPV vac-
cination programmes.
This study aimed to address this by examining both
the total annual and per patient costs of treating penile
cancer in England and also the total cost of treating a
single case from diagnosis to discharge or death.
Methods
The study was split into two phases. Firstly, to calculate
annual patient numbers, along with mean annual total
and per patient costs, a retrospective analysis was per-
formed using data extracted from Hospital Episode Sta-
tistics (HES). Each hospital Finished Consultant Episode
(FCE) results in the production of a summary of care
discharge report, containing patient demographics,
method of admission and discharge, the nature of treat-
ment carried out during the stay including any comor-
bidities and complications, and the main diagnosis that
preceded the hospital admission. Diagnoses are coded
using the International Classification of Diseases, 10th
revision (ICD-10) either as primary, related, or signifi-
cantly associated diagnoses.
Inpatient and outpatient records associated with any
of the ICD-10 codes for penile cancer were extracted for
the years 2006/07 to 2010/11 (2010/11 was representa-
tive of nine months provisional data). Since a hospital
admission may include other ICD-10 code diagnoses
where penile cancer is the secondary or tertiary diagno-
sis, a clinical expert verified that such instances should
be included within the analyses to capture the broader
burden of disease. ICD-10 codes for outpatient atten-
dances were extracted for primary and secondary diag-
noses only, as attendances are generally more disease
specific in post-treatment care. The following ICD-10
codes were used to identify eligible records: C600 -
Malignant neoplasm of prepuce, C601 - Malignant neo-
plasm of glans penis, C602 - Malignant neoplasm of
body of penis, C608 - Malignant neoplasm, overlapping
lesion of penis, C609 - Malignant neoplasm of penis, un-
specified. Penile dysplasia was not included within this
analysis as no specific ICD-10 code was available.
Approval for use of the HES data was provided by the
information asset owner from the Health and Social
Care Information Centre. The individual HES records
extracted contained no sensitive data and were pseudo-
nymised preventing the true identification of patients;
analyses pertaining to HES records adhered to published
regulations [10]. Ethical approval was not required as
secondary analysis of HES data can be used to identify
public health issues and for general medical research
under existing protocol; the Health Research Authority
decision tool corroborated this fact stating no ethical ap-
proval was required for this research [11].
Payment by Results is the payment framework for
which healthcare providers are reimbursed by commis-
sioners in England [12]. Nationally determined curren-
cies and tariffs comprise the fundamental features of
Payment by Results. The currency for inpatient care are
Healthcare Resource Groups (HRG) which are setting-
independent, clinically specified groups of diagnoses and
interventions that consume similar levels of National
Health Service resources. In contrast, the currency for
outpatient care is based on treatment function codes.
Under Payment by Results, inpatient reimbursement is
provided for a spell of care, which can potentially in-
clude multiple FCEs captured by HES. A spell is a more
robust activity measure than an FCE because FCEs can
easily be influenced (e.g. by transferring patients be-
tween consultants) in ways that spells cannot. To group
episodes of care into spells, the 2010/11 local payment
grouper was used [13]. A single core HRG was derived
reflective of the nature of treatment given during a hos-
pital stay.
Costs were considered from the healthcare payer per-
spective although ambulatory care, primary care, and
costs pertaining to high cost drugs were not considered
in the main analysis due to exclusion from HES. Hos-
pital costs were calculated using the National Tariff
2010/11 [14] and Reference Costs 2006-10 [15] for
HRGs excluded under the National Tariff. Costs were in-
flated using the consumer price index. Costs are pre-
sented (£, 2011 prices) as mean annual costs per patient
and total costs per year (based on all inpatients and out-
patients from 2006/07 to 2010/11). To compensate for
the nine months provisional data in the final year, all
costs, patient numbers and annual spells were multiplied
by a correction factor (assuming no treatment seasonal-
ity) prior to mean and standard deviation calculations.
Under HRG4, some significant elements of cost and
activity have been ‘unbundled’ from the core HRGs. The
‘unbundled component’ becomes a HRG in its own right
as an addition to a core HRG. A spell of care may
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involve several procedures and care phases (for example
diagnostic imaging, surgery and rehabilitation) each with
an individual cost. Unbundling of the tariff separates the
payment for that particular treatment, allowing different
providers to receive the costs associated with different
aspects of a procedure. Despite being constituents of
unbundled HRGs, the procurement and delivery of
chemotherapy and radiotherapy were disaggregated prior
to analysis. Statistical analysis of the HES data was con-
ducted using Statistical Analysis System Enterprise guide
4.3, and a costing algorithm was developed using Micro-
soft Excel 2007 with Visual Basic for Applications.
Due to limitations of the HES database which include
the inability to distinguish cancer stage and type (initial
versus recurrent; incident versus prevalent), the exclu-
sion of treatment costs and the short data period in
comparison to survival rates, a mathematical model of
the treatment pathway was developed in order to esti-
mate total per patient treatment costs. The treatment
pathway was based on the European Association of Ur-
ology Guidelines on Penile Cancer [16], with
probabilities for different treatment approaches taken
from published local sources and expert opinion where
necessary.
Firstly, a series of decision trees were constructed to
estimate the costs of referral, staging and treatment for
the primary tumour and local lymph nodes (Fig. 1). Each
branch of the decision tree is associated with a probabil-
ity based on publically available information and expert
opinion (please see Additional file 1). A Markov exten-
sion to the model was then used to estimate the costs of
follow-up, taking into account mortality and the prob-
ability of local, regional or distant relapse.
Figure 2 shows the structure of the Markov model.
Given that the risk of relapse tends to decrease over
time, local and regional relapse probabilities were as-
sumed to follow a Weibull distribution, with the prob-
ability of the latter falling to zero after five years [4]. For
distant relapse, the risk was assumed to be constant up
to two years after which it was assumed to be zero. The
risk of death from any of the states in the model were
also assumed to be constant.
a) Referral b) Imaging
c) Staging d) Treatment
Fig. 1 Decision tree pathways of referral, imaging, staging and treatment of primary tumour. CT; Computerised Axial Tomography; GP, General
Practitioner; GUM, Genito-Urinary Medicine; MDT, Multi-Disciplinary Team; MRI, Magnetic Resonance Imaging Rich Text Editor, my Text Field 1
Editor toolbars
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Values for all parameters detailed above, including the
time dependent risks for local and regional relapse, were
estimated by fitting the model to published data from a
large study of outcomes in penile cancer patients across
two specialist treatment centres, one in Sweden and one
in the Netherlands [4]. This was achieved using a recur-
sive algorithm, with goodness-of-fit assessed using or-
dinary least squares. Figure 3 shows the fit of the
calibrated model to data on the various types of relapse.
Consistent with the approach used in the HES ana-
lysis, costs applied in the model were taken from the
2010/11 National Tariff where the HRG associated with
a treatment or intervention was known and included
within the tariff provisions. The Reference Costs for the
same year were used for all off-tariff payments. Four
core scenarios were examined: no price inflation and no
correction for regional market forces, no price inflation
and correction for regional market forces, price inflation
(assumed to remain constant at 2011/12 levels [17]) and
no correction for regional market forces, price inflation
and correction for regional market forces. In addition, a
one way sensitivity analysis was carried out on the fol-
lowing inputs: mode of admission, costs of treatment,
intensity of follow-up, stage at presentation, approach to
primary tumour management and approach to lymph
node management. Full details of the model inputs are
available in Additional file 1.
Results
Between 2006 and 2011, an average of 640 patients were
admitted to hospital annually in England for invasive
penile cancer; 48 patients attended outpatient facilities
(Table 1). The mean age at presentation was 66 (data
not shown).
On average, there were 1,292 hospital spells and 290
outpatient attendances each year (Table 1). The mean
number of hospital spells and outpatient attendances per
patient were 2 and 6, respectively. Mean length of stay
was 5 days. Eighty-three per cent of hospital spells were
elective admissions and 21 % were day case admissions.
Excess bed days were observed in 17 % of elective and 4 %
of non-elective hospital spells.
The most frequent inpatient HRGs were penile condi-
tions with procedures of varying severity, representing 66
% of hospital spells (22 % major/intermediate procedures
and 44 % minor procedures). Bladder and urinary tract
disorders and procedures accounted for 7 % of hospital
spells.
Minor outpatient procedures were observed in 6 % of
all attendances, 25 % of which were related to pain.
Follow-up consultations were the most frequent HRG
observed in 84 % of attendances; first consultations
accounted for 10 % of attendances. The most frequent
treatment function code observed was clinical oncology
(71 % of attendances).
Chemotherapy sessions were observed in 6 % of in-
patient spells and 7 % of outpatient attendances. Radio-
therapy sessions were observed in 1 % and 37 % of
inpatient and outpatient attendances, respectively.
Across settings, palliative care was associated with 1 %
and rehabilitation with <1 % of hospital spells.
The mean annual costs per patient were estimated at
£3,737 and £1,051, for inpatients and outpatients respect-
ively (Table 1). For inpatients, £2,314,152 of the total cost
Fig. 2 Structure of the Markov Model. Note: Patients were assumed to spend only one month in any of the three relapse states before either
moving into the respective follow-up state or dying
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was attributable to bundled costs which include all care re-
ceived in a hospital setting excluding unbundled HRGs.
Unbundled costs (excluding chemotherapy and radiother-
apy) were equal to £34,291. Inpatient chemotherapy and
radiotherapy were estimated to cost £33,379 and £9,878 per
year in total, respectively (Table 2).
Outpatients accrued £28,571 bundled costs and £972
for unbundled elements of care. Chemotherapy and
radiotherapy delivered in an outpatient setting cost
£7,673 and £13,104 per year, respectively.
Bundled costs accounted for 96 % of the total annual
burden. Unbundled costs accounted for 1 %, while
chemotherapy and radiotherapy accounted for 2 % and 1
%, respectively. This proportion of bundled costs de-
creased over time from 2006 to 2009 due to improved
coding (Fig. 4).
The costs per patient derived from the mathematical
model are presented by scenario in Table 3. When using
base case inputs in the model (as presented in the tables
available in Additional file 1), the cost ranged between
£7,421 and £8,063. The lower and upper boundaries,
which are based on the uncertainty margins around the
base case inputs, are calculated to be between £5,930
and £10,968. In the one way sensitivity analysis, the
main contributors to variation in the estimates were
found to be the unit costs for interventions and the
mode of admission for treatment (Table 4), with costs in
all scenarios ranging between £5,531 and £13,050.
Discussion
This study provides, to our knowledge, the first esti-
mates of annual and per patient treatment costs for














Invasive Penile Cancer 1292 (56) 640 (39) £3,737 (£145) 290 (156) 48 (13) £1,051 (£604)
Carcinoma in Situ of the Penis 178 (28) 144 (21) £1,316 (£82) * * *
SD, Standard Deviation






























Model LR Obs LR Data RR Obs RR Model DR Obs DR
Fig. 3 Observed versus predicted cumulative relapse rates. Obs, observed; LR, local relapse; RR, regional relapse; DR, distant relapse
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penile cancer in England. Good knowledge of resource
use with existing treatments is crucial for the estimation
of opportunity costs associated with new treatments.
Therefore, this information may be used to inform re-
source allocation decisions concerning the treatment
and prevention of penile cancer in the future.
Our analysis shows that between 2006 and 2010, the
mean annual costs of treating invasive penile cancer to-
talled £3,737 per inpatient and £1,051 per outpatient,
with total mean annual costs amounting to £2,442,020
(excluding high cost drugs). The mean cost of a full
course of treatment, including follow-up, was estimated
to be between £7,421 and £8,063. This latter cost is
broadly consistent with what has been observed for
other urological cancers, with per patient treatment
costs for bladder and prostate cancer estimated to be
£8,349 and £7,294, respectively [18].
In the analysis of HES data, information routinely col-
lected in patient medical records from all English hospi-
tals were extracted solely on the presence of penile
cancer related ICD-10 codes. Up to twenty diagnosis
fields are available per FCE within patient records, thus
restricting the presence of an ICD-10 code to the tertiary
and secondary diagnosis for inpatients and outpatients
Table 2 Mean total annual costs per category of cost from the payers’ perspective
Bundled (SD) Unbundled** (SD) Chemotherapy (SD) Radiotherapy (SD) Total
Inpatient
Invasive Penile Cancer £2,314,152 (£85,368) £34,291 (£18,403) £33,379 (£18,707) £9,878 (£11,155) £2,391,700
Carcinoma in Situ of the Penis £188,499 (£19,411) £34 (£76) £573 (£1,098) £0 (£0) £189,106
Outpatient
Invasive Penile Cancer £28,571 (£14,689) £972 (£1,268) £7,673 (£9,475) £13,104 (£13,235) £50,320
Carcinoma in Situ of the Penis * * * * *
SD, Standard Deviation
In this table, *corresponds to a figure between 1 and 5. These have been suppressed as per the Hospital Episode Statistics analysis guide























Bundled Unbundled* Chemotherapy Radiotherapy
(preliminary) 
Fig. 4 Invasive penile cancer cost distribution per care type. *Excludes chemotherapy and radiotherapy. Note: 2010 figures are based on
preliminary data
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may have introduced minor selection bias inherent with
case series and furthermore led to potential underesti-
mations. Likewise, costs totally extraneous to penile can-
cer could have been introduced in the analysis if the
diagnosis restrictions were removed.
Furthermore, it is apparent from the results that the
HES outpatient dataset is not fully complete, as the vast
majority of inpatients would be expected to have at least
one single outpatient consultation. Other gaps were
found as a result of the system's dependence on clinical
coding, especially in the data from earlier years. No costs
could be applied to coding errors that arose from such
dependence (e.g. missing operational procedure codes,
invalid codes for admission or discharge, and absent age
fields). Improved training and national audits have aug-
mented this clinical coding process, and hospitals now
have explicit incentives for coding data correctly. None-
theless, these gaps and deficiencies in the dataset have
most likely led to some underestimation of the total bur-
den associated with treatment.
There were additional limitations surrounding the use
of HRGs and the National Tariff. High cost drugs are ex-
cluded and no indication of hospital prescribing data is
available within HES and therefore was not considered
in this analysis. Moreover, costs associated with
unbundled HRGs are not available in the National Tariff
due to wide regional variations in resource use and cost.
We therefore used the National Reference Costs which
provides the foundations for the National Tariff. Defini-
tions for HRGs may vary per year and matching codes
and definitions could have led to under- or over-
estimations of the economic burden.
The HES data also lacked specificity. It was not pos-
sible to determine a patient's stage at diagnosis or track
the interventions received through time. Therefore, to
estimate total costs per patient we developed a mathem-
atical model to simulate the treatment pathway for the
average penile cancer patient. This model was also sub-
ject to limitations. Firstly, although local data were ap-
plied where possible, the relapse rates used to estimate
the transition probabilities in the Markov portion of the
model derive from international data, where treatment
may not reflect clinical practice in the United Kingdom.
The method used to calibrate the model to these data
was unable to reflect the uncertainty in these estimates,
and any future models would benefit from further ex-
ploration of this issue. Furthermore, we were unable to
reflect the impact of primary treatment on the likelihood
of relapse due to the format of data reporting in the
Leijte et al study [4].
However, the overall fit of the model to available data
was good, with cost estimates broadly consistent with
comparable cancer areas. The findings also revealed that
costs tended to be insensitive to choices in treatment
modality, for example aggressive versus conservative
treatment for patients with suspected lymph node in-
volvement, and that the biggest determinant of overall
treatment costs is the setting in which care is delivered.
Conclusion
Despite being rare compared to other malignancies
treated by urologists, such as prostate and bladder can-
cer, penile cancer still has important resource implica-
tions which must be accounted for, especially in the
context of investment decisions relating to specialist
treatment centres. The findings of our study further
highlight the potential economic benefits of measures
aimed at preventing penile cancers including the promo-
tion of good hygiene practices and HPV vaccination.
Table 3 Per patient treatment costs by scenario
Cost per Patient
Scenario Base Case Lower Bound Upper Bound
No inflation, no MFF £7,421 £5,930 £10,104
Inflation, no MFF £7,465 £5,961 £10,156
No inflation, MFF £8,015 £6,405 £10,913
Inflation, MFF £8,063 £6,437 £10,968
MFF, Market Force Factor
Table 4 Results of the one way sensitivity analysis by scenario
Scenarios
No inflation, no MFF Inflation, no MFF No inflation, MFF Inflation, MFF
Admission £5,531-£12,029 £5,573-£12,083 £5,973-£12,991 £6,019-£13,050
Costsa £6,116-£9,746 £6,147-£9,796 £6,606-£10,526 £6,639-£10,580
Intensity of follow-up £7,133-£7,656 £7,166-£7,704 £7,704-£8,269 £7,739-£8,320
Stage at presentation £7,304-£7,604 £7,347-£7,650 £7,888-£8,212 £7,935-£8,262
Lymph node management £7,368-£7,480 £7,412-£7,524 £7,957-£8,078 £8,005-£8,126
Primary tumour management £7,373-£7,469 £7,418-£7,513 £7,963-£8,067 £8,011-£8,115
MFF, Market Force Factor
aCosts for the base case mode of admission were varied
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Abbreviations
FCE: Finished Consultant Episode; HES: Hospital Episode Statistics;
HPV: Human Papillomavirus; HRG: Healthcare Resource Group; ICD-10: 10th
revision of the International Statistical Classification of Diseases and Related
Health Problems.
Competing interests
At the time of manuscript preparation, SK and SC were employees of Sanofi
Pasteur MSD. MT and SS were employees of Pharmerit Ltd, which received
funding from Sanofi Pasteur MSD. VS has no competing interests to declare.
Authors’ contributions
SK, SC, SS and MT participated in the study design and acquisition of the
data. SK and MT participated in the statistical analysis. All authors
participated in the analysis and interpretation of the data and drafting of the
manuscript. SC, SS and VS conducted a critical revision of the manuscript for
important intellectual content. All authors read and approved the final
manuscript.
Acknowledgements
We acknowledge and thank Simon Oakley for his support in the
development of this manuscript.
Author details
1Sanofi Pasteur MSD, Mallards Reach, Bridge Avenue, Maidenhead, Berks SL6
1QP, UK. 2Pharmerit Ltd, Enterprise House, Innovation Way, York YO10 5NQ,
UK. 3The Christie NHS Foundation Trust, University Hospital of South
Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Received: 27 June 2014 Accepted: 21 December 2015
References
1. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine.
2006;24 Suppl 3:S3/11–25.
2. Bleeker MCG, Heideman D a M, Snijders PJF, Horenblas S, Dillner J, Meijer
CJLM. Penile cancer: epidemiology, pathogenesis and prevention. World J
Urol. 2009;27:141–50.
3. Arya M, Li R, Pegler K, Sangar V, Kelly JD, Minhas S, et al. Long-term trends
in incidence, survival and mortality of primary penile cancer in England.
Cancer Causes Control. 2013;24:2169–76.
4. Leijte JAP, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence
patterns of squamous cell carcinoma of the penis: recommendations for
follow-up based on a two-centre analysis of 700 patients. Eur Urol.
2008;54:161–8.
5. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men.
Prev Med (Baltim). 2011;53 Suppl 1:S36–41.
6. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell
carcinoma of the penis. Scand J Urol Nephrol Suppl. 2000;189–93.
7. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S.
Human papillomavirus prevalence and type distribution in penile
carcinoma. J Clin Pathol. 2009;62:870–8.
8. Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T. EAU Guidelines on
Penile Cancer. Eur Urol. 2004;46:1–8.
9. Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer
sufferers: a systematic review of the quality of life, psychosexual and
psychosocial literature in penile cancer. BMC Urol. 2009;9:8.
10. Information Centre: The HES Protocol (June 2009). London: NHS Health and
Social Care Information Centre; 2009. http://www.hscic.gov.uk/media/10475/
HES-Protocol/pdf/HESProtocol.pdf.
11. NHS Research Ethics Committee Decision Tool [http://www.hra-decision
tools.org.uk/ethics/].
12. Payment by Results in the NHS: A Simple Guide [https://www.gov.uk/
government/publications/simple-guide-to-payment-by-results].
13. HRG 4 2010/11 Local Payment Grouper [http://www.hscic.gov.uk/article/
2332/HRG4-201011-Local-Payment-Grouper-Documentation].
14. 2010-11 National Tariff [http://data.gov.uk/dataset/payment-by-results-2010-
11-national-tariff-information].
15. 2010-11 Reference Costs [https://www.gov.uk/government/publications/
2010-11-reference-costs-publication].
16. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, et al.
EAU penile cancer guidelines 2009. Eur Urol. 2010;57:1002–12.
17. Consumer Price Indices (August Dataset) [http://www.ons.gov.uk/ons/rel/
cpi/consumer-price-indices/august-2012/cpi-time-series-data.html].
18. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The
economic consequences of prostate and bladder cancer in the UK. BJU Int.
2005;95:59–63.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Keeping et al. BMC Public Health  (2015) 15:1305 Page 8 of 8
